Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedAug 27, 2025
DataAggregated Company Financials
Companies62
  • 7D-1.5%
  • 3M15.4%
  • 1Y-20.9%
  • YTD-9.7%

Over the last 7 days, the Life Sciences industry has dropped 1.5%, driven by declines in Danaher and Thermo Fisher Scientific of 2.8% and 2.0%, respectively. The industry has fallen 21% in the last year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 27 Aug 2025US$583.2bUS$144.1bUS$14.5b28.8x40.2x4x
Fri, 25 Jul 2025US$565.9bUS$143.6bUS$8.8b41.6x64.4x3.9x
Sun, 22 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Tue, 20 May 2025US$519.6bUS$142.7bUS$9.1b33.4x57.2x3.6x
Thu, 17 Apr 2025US$517.3bUS$142.6bUS$10.0b35x52x3.6x
Sat, 15 Mar 2025US$581.3bUS$143.1bUS$9.8b38.6x59.5x4.1x
Mon, 10 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Wed, 08 Jan 2025US$673.1bUS$142.4bUS$10.2b43.9x66x4.7x
Fri, 06 Dec 2024US$671.2bUS$142.4bUS$10.2b43.6x65.7x4.7x
Sun, 03 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Tue, 01 Oct 2024US$748.6bUS$141.8bUS$8.5b39x88.1x5.3x
Thu, 29 Aug 2024US$745.7bUS$141.8bUS$8.5b37.7x87.8x5.3x
Sat, 27 Jul 2024US$716.0bUS$141.0bUS$12.5b37.3x57.4x5.1x
Mon, 24 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Wed, 22 May 2024US$739.8bUS$141.5bUS$12.4b38.5x59.5x5.2x
Fri, 19 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Sun, 17 Mar 2024US$742.0bUS$142.1bUS$12.8b43.9x57.8x5.2x
Tue, 13 Feb 2024US$709.9bUS$141.9bUS$12.7b39.2x55.8x5x
Thu, 11 Jan 2024US$692.8bUS$153.9bUS$14.2b36.6x48.9x4.5x
Sat, 09 Dec 2023US$648.8bUS$153.7bUS$14.0b35.2x46.3x4.2x
Mon, 06 Nov 2023US$595.2bUS$153.9bUS$11.0b31.5x54x3.9x
Wed, 04 Oct 2023US$640.4bUS$154.6bUS$11.2b32.3x57.2x4.1x
Fri, 01 Sep 2023US$733.5bUS$154.6bUS$11.2b32.9x65.4x4.7x
Sun, 30 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Tue, 27 Jun 2023US$687.9bUS$152.4bUS$12.5b29.3x55x4.5x
Thu, 25 May 2023US$671.4bUS$152.2bUS$12.5b27.8x53.7x4.4x
Sat, 22 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Mon, 20 Mar 2023US$700.9bUS$154.5bUS$10.8b27.3x64.8x4.5x
Wed, 15 Feb 2023US$749.4bUS$154.2bUS$8.6b32.4x87.2x4.9x
Fri, 13 Jan 2023US$756.5bUS$155.3bUS$8.5b30.4x88.7x4.9x
Sun, 11 Dec 2022US$761.9bUS$155.1bUS$8.8b28.4x86.8x4.9x
Tue, 08 Nov 2022US$707.8bUS$154.9bUS$9.1b26.4x78.1x4.6x
Thu, 06 Oct 2022US$758.4bUS$152.5bUS$17.0b25x44.6x5x
Sat, 03 Sep 2022US$753.3bUS$152.3bUS$17.3b28.7x43.5x4.9x
Price to Earnings Ratio

43.5x


Total Market Cap: US$753.3bTotal Earnings: US$17.3bTotal Revenue: US$152.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.2x which is lower than its 3-year average PE of 61.9x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 5.7% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.32%
Healthcare0.40%
Life Sciences-1.53%
Clinical Research and Equipment-1.53%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TEM Tempus AIUS$76.304.4%
+US$559.4m		11.4%PS13.9x
CRL Charles River Laboratories InternationalUS$163.713.3%
+US$257.4m		-19.5%PS2x
TECH Bio-TechneUS$56.793.5%
+US$231.8m		-20.0%PE120.4x
BIO Bio-Rad LaboratoriesUS$296.602.9%
+US$222.7m		-7.1%PE25.1x
AVTR AvantorUS$13.302.5%
+US$218.2m		-48.1%PE13.2x

Latest News

MTD
US$1,284.77
Mettler-Toledo International
7D
-2.9%
1Y
-9.7%

Pharmaceutical And Food Production Expansions Will Unlock Future Opportunities

The consensus Analyst Price Target for Mettler-Toledo International saw a marginal upward revision from $1,276 to $1,295, as key valuation metrics such as Future P/E and Discount Rate remained essentially unchanged. What's in the News Repurchased 197,053 shares (0.95%) for $218.74 million between April and June 2025; total buyback now 17,527,389 shares (64.7%) for $9,152.11 million under program initiated in 2010.
TECH
US$56.79
Bio-Techne
7D
3.5%
1Y
-20.0%

Chronic Disease Trends And Precision Medicine Will Shape Demand

Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.
TEM
US$76.30
Tempus AI
7D
4.4%
1Y
11.4%

Expanding Genomic Testing And AI Will Build Lasting Healthcare Value

Tempus AI's slightly higher consensus price target reflects a significant increase in its future P/E ratio despite a decline in net profit margin, resulting in a new fair value estimate of $71. What's in the News Tempus AI filed a $500 million follow-on equity offering of Class A Common Stock via an at-the-market transaction and raised its full-year 2025 revenue guidance to approximately $1.26 billion, representing ~82% annual growth.
CRL
US$163.71
Charles River Laboratories International
7D
3.3%
1Y
-19.5%

Advanced Therapeutics Adoption Will Transform Preclinical Capabilities

Charles River Laboratories’ price target was raised to $172.07 following a strong Q2 beat, renewed demand stability, and valuation support from strategic review and activist involvement, partially offset by lingering uncertainty into late 2025. Analyst Commentary Q2 results exceeded expectations with sales 5% above consensus and a significant adjusted EPS beat, indicating improving operational performance.
TMO
US$488.48
Thermo Fisher Scientific
7D
-2.0%
1Y
-20.0%

Pharmaceutical And Biotech Expansion Will Fuel Future Success

Analysts raised their price target for Thermo Fisher Scientific to $555.84, citing improved sentiment from strong Q2 results, upward FY25 guidance revisions, and optimism around its resilient pharmaceutical partnership model and recovering end-markets, despite ongoing R&D headwinds. Analyst Commentary Bullish analysts highlight Thermo Fisher's resilient "one-stop-shop" pharma partnership model, expecting it to drive multiple expansion and position the company as a long-term biopharma partner of choice.
AVTR
US$13.30
Avantor
7D
2.5%
1Y
-48.1%
MEDP
US$469.29
Medpace Holdings
7D
1.5%
1Y
22.4%
A
US$118.30
Agilent Technologies
7D
-1.5%
1Y
-16.2%
ICLR
US$171.76
ICON
7D
-4.4%
1Y
-47.3%

After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar
DHR
US$206.25
Danaher
7D
-2.8%
1Y
-23.3%
ILMN
US$98.73
Illumina
7D
-2.8%
1Y
-24.6%

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues
STVN
US$21.65
Stevanato Group
7D
-3.6%
1Y
5.9%

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
FTRE
US$8.98
Fortrea Holdings
7D
13.8%
1Y
-60.7%

Global Demographic Trends Will Spur Clinical Advances

Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.
BIO
US$296.60
Bio-Rad Laboratories
7D
2.9%
1Y
-7.1%

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
ATLN
US$4.66
Atlantic International
7D
40.4%
1Y
-25.4%

Atlantic International's Position Is Risky, It Is Not An Opportunity

Aug 01
IQV
US$187.76
IQVIA Holdings
7D
-2.4%
1Y
-24.5%